Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Hegi, Lili Liu, J. Herman, R. Stupp, W. Wick, M. Weller, M. Mehta, M. Gilbert (2008)
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
M. Abràmoff, P. Magalhães, S. Ram (2004)
Image processing with ImageJ, 11
A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli, G. Frezza, M. Leonardi, F. Spagnolli, M. Ermani (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 13
H. Friedman, R. McLendon, T. Kerby, M. Dugan, S. Bigner, AJ Henry, D. Ashley, J. Krischer, S. Lovell, K. Rasheed, F. Marchev, AJ Seman, I. Cokgor, J. Rich, E. Stewart, Colvin Om, J. Provenzale, D. Bigner, Michael Haglund, A. Friedman, P. Modrich (1998)
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 12
W. Pope, A. Lai, R. Mehta, Hyun Kim, J. Qiao, J. Young, X. Xue, Jonathan Goldin, Matthew Brown, P. Nghiemphu, A. Tran, T. Cloughesy (2011)
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated GlioblastomaAmerican Journal of Neuroradiology, 32
W. Moon, Jin Choi, H. Roh, S. Lim, Y. Koh (2012)
Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imagingNeuroradiology, 54
A. Nygren, N. Ameziane, Helena Duarte, R. Vijzelaar, Q. Waisfisz, C. Hess, J. Schouten, A. Errami (2005)
Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequencesNucleic Acids Research, 33
S. Higano, Xia Yun, T. Kumabe, Mika Watanabe, S. Mugikura, A. Umetsu, A. Sato, Takayuki Yamada, Shoki Takahashi (2006)
Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis.Radiology, 241 3
Joonmi Oh, R. Henry, A. Pirzkall, Ying Lu, Xiaojuan Li, I. Catalaa, Susan Chang, W. Dillon, S. Nelson (2004)
Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volumeJournal of Magnetic Resonance Imaging, 19
Yusuhn Kang, S. Choi, Young-Jae Kim, K. Kim, C. Sohn, Ji-hoon Kim, T. Yun, K. Chang (2011)
Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade.Radiology, 261 3
R. Stupp, P. Dietrich, Sandrine Kraljevic, A. Pica, I. Maillard, P. Maeder, R. Meuli, R. Janzer, G. Pizzolato, R. Miralbell, F. Porchet, L. Regli, N. Tribolet, R. Mirimanoff, S. Leyvraz (2002)
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
M. Preusser, M. Hassler, K. Elandt, E. Gelpí, J. Hainfellner, M. Baur, C. Marosi (2007)
Analysis of MGMT promoter methylation status in high grade glioma patients with long term and conventional survival times: A retrospective studyJournal of Clinical Oncology, 25
R. Kiss, O. Dewitte, C. Decaestecker, I. Camby, L. Gordower, K. Delbecque, J. Pasteels, J. Brotchi, I. Salmon (1997)
The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors.American journal of clinical pathology, 107 3
S. Hsu, L. Raine, H. Fanger (1981)
A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies.American journal of clinical pathology, 75 5
S. Drabycz, G. Roldán, Paula Robles, D. Adler, John McIntyre, Anthony Magliocco, J. Cairncross, J. Mitchell (2010)
An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imagingNeuroImage, 49
M. Esteller, Jesús García-Foncillas, E. Andion, Steven Goodman, Oscar Hidalgo, V. Vanaclocha, S. Baylin, James Herman (2000)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.The New England journal of medicine, 343 19
D. Kong, S.T. Kim, E. Kim, D. Lim, W. Kim, Y. Suh, J. Lee, K. Park, J.H. Kim, D. Nam (2011)
Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation StatusAmerican Journal of Neuroradiology, 32
F. Davis, S. Freels, J. Grutsch, S. Barlas, S. Brem (1998)
Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.Journal of neurosurgery, 88 1
P. Wen, D. MacDonald, D. Reardon, T. Cloughesy, A. Sorensen, E. Galanis, J. Degroot, W. Wick, M. Gilbert, A. Lassman, C. Tsien, T. Mikkelsen, Eric Wong, M. Chamberlain, R. Stupp, K. Lamborn, M. Vogelbaum, M. Bent, Susan Chang (2010)
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
T. Jung, Shin Jung, Kyung-Sub Moon, In-Young Kim, Sam‐Suk Kang, Young-Hee Kim, Chang‐soo Park, Kyung-Hwa Lee (2010)
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.Oncology reports, 23 5
M. Hegi, A. Diserens, T. Gorlia, M. Hamou, N. Tribolet, N. Tribolet, M. Weller, J. Kros, J. Hainfellner, W. Mason, L. Mariani, Jacoline Bromberg, P. Hau, R. Mirimanoff, J. Cairncross, R. Janzer, R. Stupp (2005)
MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 352
J. Henson, P. Gaviani (2005)
MRI in treatment of adult gliomas.The Lancet. Oncology, 6 3
A. Stark, A. Nabavi, H. Mehdorn, U. Blömer (2005)
Glioblastoma multiforme-report of 267 cases treated at a single institution.Surgical neurology, 63 2
deAngelis (2001)
Brain tumorsN Engl J Med, 344
T. Scholzen, J. Gerdes (2000)
The Ki‐67 protein: From the known and the unknownJournal of Cellular Physiology, 182
D. Tozer, H. Jäger, N. Danchaivijitr, C. Benton, P. Tofts, J. Rees, A. Waldman (2007)
Apparent diffusion coefficient histograms may predict low‐grade glioma subtypeNMR in Biomedicine, 20
D. Patterson, A. Padhani, D. Collins (2008)
Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapyNature Clinical Practice Oncology, 5
Chul-Kee Park, Jinwook Kim, S. Yim, A. Lee, J. Han, Chae-Yong Kim, Sung-Hye Park, T. Kim, Se-Hoon Lee, S. Choi, Seung-Ki Kim, D. Kim, Hee-Won Jung (2011)
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.Neuro-oncology, 13 2
L. D. (2005)
Brain tumorsPsychiatric Quarterly, 4
P. Hau, R. Stupp, M. Hegi (2007)
MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?Disease Markers, 23
M. Diehn, C. Nardini, David Wang, S. McGovern, M. Jayaraman, Yu Liang, K. Aldape, S. Cha, M. Kuo (2008)
Identification of noninvasive imaging surrogates for brain tumor gene-expression modulesProceedings of the National Academy of Sciences, 105
Jihong Zhang, M. Stevens, C. Laughton, S. Madhusudan, T. Bradshaw (2010)
Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational ApplicationsOncology, 78
J. Jeuken, S. Cornelissen, Martine Vriezen, Marieke Dekkers, A. Errami, A. Sijben, Sandra Boots-Sprenger, P. Wesseling (2007)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomasLaboratory Investigation, 87
Purpose: To retrospectively determine whether the apparent diffusion coefficient (ADC) values correlate with O6‐methylguanine DNA methyltransferase (MGMT) promoter methylation semiquantitatively analyzed by methylation‐specific multiplex ligation‐dependent probe amplification (MS‐MLPA) in patients with glioblastoma. Materials and Methods: The study was approved by the Institutional Review Board and was Health Insurance Portability and Accountability Act (HIPAA) compliant. Newly diagnosed patients with glioblastoma (n = 26) were analyzed with an ADC histogram approach based on enhancing solid portion. The methylation status of MGMT promoter was assessed by methylation‐specific polymerase chain reaction (MSP) and by MS‐MLPA. MS‐MLPA is a semiquantitative method that determines the methylation ratio. The Ki‐67 labeling index was also analyzed. The mean and 5th percentile ADC values were correlated with MGMT promoter methylation status and Ki‐67 labeling index using a linear regression model. Progression‐free survival (PFS) was also correlated with the ADC values using Kaplan–Meier survival analysis. Results: The mean methylation ratio was 0.21 ± 0.20. By MSP, there were 5 methylated and 21 unmethylated tumors. The mean ADC revealed a positive relationship with MGMT promoter methylation ratio (P = 0.015) and was also significantly different according to MSP‐determined methylation status (P = 0.011). Median PFS was significantly related with methylation ratio (P = 0.017) and MSP‐derived methylation status (P = 0.025). A positive relationship was demonstrated between PFS and the mean ADC value (P = 0.001). The 5th percentile ADC values showed a significant negative relationship with Ki‐67 labeling index (P = 0.036). Conclusion: We found that ADC values were significantly correlated with PFS as well as with MGMT promoter methylation status. We believe that ADC values may merit further investigation as a noninvasive biomarker for predicting treatment response. J. Magn. Reson. Imaging 2013;37:351–358. © 2012 Wiley Periodicals, Inc.
Journal of Magnetic Resonance Imaging – Wiley
Published: Feb 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.